Advertisement
U.S. markets closed
S&P Futures
5,888.25 -8.00 (-0.14%) Dow Futures
43,134.00 -43.00 (-0.10%) Nasdaq Futures
20,473.50 -46.00 (-0.22%) Russell 2000 Futures
2,250.80 -4.70 (-0.21%) Crude Oil
70.27 -0.29 (-0.41%) Gold
2,743.40 +4.50 (+0.16%)
At close: 04:00PM EDT
| Previous Close | 2.0000 |
| Open | 2.0200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.9650 - 2.0700 |
| 52 Week Range | 1.5500 - 2.7500 |
| Volume | |
| Avg. Volume | 11,171 |
| Market Cap | 7.451M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9800 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)
Pulmatrix ( NASDAQ:PULM ) Second Quarter 2024 Results Key Financial Results Revenue: US$1.55m (down 16% from 2Q 2023...
PR NewswirePulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.